Opthea to Delist from Nasdaq, Focuses on ASX and Australian Market
Opthea Limited (AU:OPT) has announced its voluntary delisting from the Nasdaq Stock Market, while retaining its listing on the Australian Securities Exchange (ASX). This decision aims to streamline operations and reduce costs, focusing on the Australian market to enhance shareholder value. The company will continue its American Depositary Receipt program for U.S. investors in the OTC market. The latest analyst rating for Opthea stock is a Sell, with a price target of A$0.05. Current market cap stands at A$738.8M.
The latest announcement is out from Opthea ( (AU:OPT) ).
Opthea Limited has announced its decision to voluntarily delist from the Nasdaq Stock Market while maintaining its listing on the Australian Securities Exchange (ASX). This strategic move is aimed at streamlining operations, reducing costs, and focusing on the Australian market to enhance long-term shareholder value. The company plans to continue its American Depositary Receipt program to facilitate trading for U.S. investors in the OTC market, aligning its structure with operational priorities.
The most recent analyst rating on (AU:OPT) stock is a Sell with a A$0.05 price target. To see the full list of analyst forecasts on Opthea stock, see the AU:OPT Stock Forecast page.
More about Opthea
Opthea Limited is a biopharmaceutical company focused on developing novel therapies to treat diseases mediated by Vascular Endothelial Growth Factors (VEGF) C and/or D.
Technical Sentiment Signal: Sell
Current Market Cap: A$738.8M
